{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:44Z","timestamp":1792239044735,"version":"4.4.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein\u2013coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.<\/jats:p>","DOI":"10.1038\/s41375-024-02482-6","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T02:18:09Z","timestamp":1737944289000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maung M.","family":"Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing C.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Puliafito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-4618","authenticated-orcid":false,"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-4007","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-2864","authenticated-orcid":false,"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelak","family":"Biru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2482_CR1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2482_CR2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"2482_CR3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2482_CR4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2482_CR5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2482_CR6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"2482_CR7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"2482_CR8","doi-asserted-by":"crossref","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol 2024;25:e374\u201387.","DOI":"10.1016\/S1470-2045(24)00094-9"},{"key":"2482_CR9","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, Gallego Perez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u2013e216.","journal-title":"Lancet Oncol"},{"key":"2482_CR10","doi-asserted-by":"crossref","unstructured":"Yi L, Thomas GM, Usmani, SZ, Jesus GB, Jakubowiak, AJ, Agha, ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:809.","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"2482_CR11","doi-asserted-by":"crossref","unstructured":"Mateos MV, San Miguel J, Dhakal B, Touzeau C, Leleu X, Van de Donk NW, et al. Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update. Int Myeloma Soc; 2024; Rio de Janeiro, Brazil; 2024.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"2482_CR12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98:S13\u201321.","journal-title":"Am J Hematol"},{"key":"2482_CR13","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk N, Moreau P, Bhutani M, Oriol A. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:7540.","journal-title":"J Clin Oncol"},{"key":"2482_CR14","unstructured":"Mohty M, Iida S, Bahlis NJ, Sullivan S, Conte U, Leip E Abstract P932: Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3. European Hematology Association. Madrid, Spain; 2024."},{"key":"2482_CR15","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"},{"key":"2482_CR16","doi-asserted-by":"crossref","unstructured":"Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D\u2019Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol 2023;203:736\u201346.","DOI":"10.1111\/bjh.18909"},{"key":"2482_CR17","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255\u2013e269.","journal-title":"Lancet Oncol"},{"key":"2482_CR18","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos M-V, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036\u20138036.","journal-title":"J Clin Oncol"},{"key":"2482_CR19","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1002\/hem3.104","volume":"8","author":"L Rasche","year":"2024","unstructured":"Rasche L, Schinke C, Touzeau C, Minnema M, van de Donk N, Rodriguez-Otero P, et al. Long-term efficacy and safety results from the phase 1\/2 monumental-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple Myeloma. Hemasphere. 2024;8:e104.","journal-title":"Hemasphere"},{"key":"2482_CR20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"2482_CR21","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti-G protein-coupled receptor, Class C Group 5 Member D Chimeric Antigen Receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583\u201393.","journal-title":"J Clin Oncol"},{"key":"2482_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal S, Htut M, Nadeem O, Anderson LD Jr, Ko\u00e7o\u011flu H, Gregory T, et al. BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study. Blood. 2023;142:219.","journal-title":"Blood"},{"key":"2482_CR23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","volume":"10","author":"W Qiang","year":"2024","unstructured":"Qiang W, Lu J, Jia Y, Liu J, Liu J, He H, et al. B-Cell Maturation Antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma. JAMA Oncol. 2024;10:1259\u201363.","journal-title":"JAMA Oncol"},{"key":"2482_CR24","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024;11:e751\u201360.","journal-title":"Lancet Haematol"},{"key":"2482_CR25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29:422\u20139.","journal-title":"Nat Med"},{"key":"2482_CR26","doi-asserted-by":"crossref","unstructured":"Dholaria B, Kocoglu MH, Andrew K, Ramakrishnan A, Shune L, Ganguly S, et al. A Phase 1 Study of P\u2010BCMA\u2010 ALLO1, a Non\u2010viral, Allogeneic BCMA Directed CAR\u2010T in Relapsed\/ Refractory Multiple Myeloma (RRMM). Int Myeloma Soc, 2024; Rio de Janeiro, Brazil; 2024.","DOI":"10.1016\/S2152-2650(24)01845-7"},{"key":"2482_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study. Blood. 2021;138:157.","journal-title":"Blood"},{"key":"2482_CR28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"2482_CR29","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u201312.","journal-title":"Lancet Haematol"},{"key":"2482_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl J Med. 2024;391:393\u2013407.","journal-title":"N. Engl J Med"},{"key":"2482_CR31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N. Engl J Med. 2024;391:408\u201321.","journal-title":"N. Engl J Med"},{"key":"2482_CR32","first-page":"1794","volume":"130","author":"M Works","year":"2017","unstructured":"Works M, Soni N, Hauskins C, Sierra C, Baturevych A, Jones JA. Lenalidomide Enhances Anti-BCMA Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma. Blood. 2017;130:1794.","journal-title":"Blood"},{"key":"2482_CR33","doi-asserted-by":"crossref","first-page":"e00184","DOI":"10.1097\/BS9.0000000000000184","volume":"6","author":"J Zhao","year":"2024","unstructured":"Zhao J, Yang H, Ge J, Li L, Yao Q, He S, et al. Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia\/lymphoma with extramedullary disease. Blood Sci. 2024;6:e00184.","journal-title":"Blood Sci"},{"key":"2482_CR34","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"SF Cho","year":"2020","unstructured":"Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4:4195\u2013207.","journal-title":"Blood Adv"},{"key":"2482_CR35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2:354\u201369.","journal-title":"Blood Cancer Discov"},{"key":"2482_CR36","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41:2594\u2013606.","journal-title":"J Clin Oncol"},{"key":"2482_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Martin-Lopez AA, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-Cell lymphoma receiving chimeric antigen receptor T-Cell therapy. J Clin Oncol. 2024;42:205\u201317.","journal-title":"J Clin Oncol"},{"key":"2482_CR38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"2482_CR39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.19227","volume":"204","author":"S Bal","year":"2024","unstructured":"Bal S, Costa LJ. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma. Br J Haematol. 2024;204:449\u201354.","journal-title":"Br J Haematol"},{"key":"2482_CR40","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1182\/blood-2022-167804","volume":"140","author":"R Villanueva","year":"2022","unstructured":"Villanueva R, Hansen DK, Tonseth RP, Gage KL, Wei Z, De Avila G, et al. High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma. Blood. 2022;140:10402\u20134.","journal-title":"Blood"},{"key":"2482_CR41","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by Anti-CD19 Chimeric Antigen Receptor T cells are associated with high serum interleukin-15 Levels. J Clin Oncol. 2017;35:1803\u201313.","journal-title":"J Clin Oncol"},{"key":"2482_CR42","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.","journal-title":"Sci Transl Med"},{"key":"2482_CR43","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3324\/haematol.2022.282490","volume":"108","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonzalez-Calle V, Sureda A, Moreno MJ, Oriol A, Gonzalez E, et al. Randomized phase II study of weekly carfilzomib 70 mg\/m(2) and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients. Haematologica. 2023;108:2753\u201363.","journal-title":"Haematologica"},{"key":"2482_CR44","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284\u201390.","journal-title":"Blood"},{"key":"2482_CR45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"2482_CR46","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"2482_CR47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","volume":"126","author":"C Gasparetto","year":"2022","unstructured":"Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Baljevic M, Lentzsch S, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer. 2022;126:718\u201325.","journal-title":"Br J Cancer"},{"key":"2482_CR48","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2021-154071","volume":"138","author":"N Watts","year":"2021","unstructured":"Watts N, Giri S, Godby KN, Ravi G, Costa LJ, Bal S. High dose fractionated cyclophosphamide, vincristine, doxorubicin, and Dexamethasone (mHyperCVAD) Is an active regimen in heavily pretreated relapsed\/refractory multiple myeloma, enabling access to experimental therapies. Blood. 2021;138:3784.","journal-title":"Blood"},{"key":"2482_CR49","first-page":"504.e501","volume":"29","author":"A Zafar","year":"2023","unstructured":"Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, et al. Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2023;29:504.e501\u20137.","journal-title":"Transpl Cell Ther"},{"key":"2482_CR50","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S2152-2650(24)01929-3","volume":"24","author":"K Godby","year":"2024","unstructured":"Godby K, Bal S, Giri S, Ravi G, Joiner L, Hagedorn C, et al. Combined GPRC5D and BCMA-targeted T-cell Redirecting Therapy in the Treatment of RRMM. Clin Lymphoma Myeloma Leuk. 2024;24:S55\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2482_CR51","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S2152-2650(24)01981-5","volume":"24","author":"H Shaikh","year":"2024","unstructured":"Shaikh H, Lochner J, Davis J, Snyder J, Friend R, Patrus G, et al. Prompt and profound responses with talquetamab in patients with heavily pretreated relapsed-refractory multiple myeloma \u2013 another bridging therapy. Clin Lymphoma Myeloma Leuk. 2024;24:S86\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2482_CR52","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, et al. The safety of bridging radiation with anti-BCMA CAR T-Cell therapy for multiple myeloma. Clin Cancer Res. 2021;27:6580\u201390.","journal-title":"Clin Cancer Res"},{"key":"2482_CR53","doi-asserted-by":"crossref","unstructured":"Sperling AS, Nikiforow S, Derman B, Nadeem O, Mo C, Laubach J, et al. Phase I Study Data Update of PHE885, a Fully Human BCMA-directed CAR-T Cell Therapy Manufactured Using the T-Charge(TM) Platform for Patients with Relapsed\/Refractory (R\/R) Multiple Myeloma (MM). Hemasphere 2022; 6;2572\u20139241.","DOI":"10.1097\/01.HS9.0000848640.53562.8f"},{"key":"2482_CR54","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15:3371.","journal-title":"Nat Commun"},{"key":"2482_CR55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328.","journal-title":"Blood"},{"key":"2482_CR56","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322.","journal-title":"Clin Cancer Res"},{"key":"2482_CR57","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3:2812\u20135.","journal-title":"Blood Adv"},{"key":"2482_CR58","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11:e693\u2013707.","journal-title":"Lancet Haematol"},{"key":"2482_CR59","doi-asserted-by":"crossref","unstructured":"Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, et al. Absolute lymphocyte count and outcomes of multiple myeloma patients treated with idecabtagene vicleucel: the us myeloma immunotherapy consortium real- world experience. Transplant Cell Ther. 2024; 30:790.e1\u2013790.e16.","DOI":"10.1016\/j.jtct.2024.05.025"},{"key":"2482_CR60","doi-asserted-by":"publisher","unstructured":"Lee H, Durante MA, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood 2024. https:\/\/doi.org\/10.1182\/blood.2024026212 Epub ahead of print.","DOI":"10.1182\/blood.2024026212"},{"key":"2482_CR61","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","volume":"7","author":"MK Samur","year":"2023","unstructured":"Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7:6599\u2013603.","journal-title":"Blood Adv"},{"key":"2482_CR62","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"2482_CR63","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021;5:3794\u20138.","journal-title":"Blood Adv"},{"key":"2482_CR64","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024;144:402\u20137.","journal-title":"Blood"},{"key":"2482_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"2482_CR66","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"2482_CR67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"2482_CR68","doi-asserted-by":"publisher","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood 2024. https:\/\/doi.org\/10.1182\/blood.2024025945.","DOI":"10.1182\/blood.2024025945"},{"key":"2482_CR69","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer J. 2023;13:76.","journal-title":"Blood Cancer J"},{"key":"2482_CR70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2023-180006","volume":"142","author":"F Smits","year":"2023","unstructured":"Smits F, Groen K, Levin M-D, Stege C, Van Kampen RJW, Van Der Spek E, et al. Dynamic frailty status enables better prediction of survival probability - results of the HOVON 143 study. Blood. 2023;142:342.","journal-title":"Blood"},{"key":"2482_CR71","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023;13:6.","journal-title":"Blood Cancer J"},{"key":"2482_CR72","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1200\/JCO.2023.41.16_suppl.8040","volume":"41","author":"NS Raje","year":"2023","unstructured":"Raje NS, Leleu XP, Lesokhin AM, Mohty M, Nooka AK, Leip E, et al. Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed\/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3. J Clin Oncol. 2023;41:8040.","journal-title":"J Clin Oncol"},{"key":"2482_CR73","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jtct.2024.04.002","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis J, Ahmed N, Sannareddy A, Shaikh H, Shune L, et al. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC). Transplant Cell Ther. 2024;30:S384\u20135.","journal-title":"Transplant Cell Ther"},{"key":"2482_CR74","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","volume":"30","author":"JA Davis","year":"2024","unstructured":"Davis JA, Dima D, Ahmed N, DeJarnette S, McGuirk J, Jia X, et al. Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma. Transpl Cell Ther. 2024;30:298\u2013305.","journal-title":"Transpl Cell Ther"},{"key":"2482_CR75","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","volume":"142","author":"S Sidana","year":"2023","unstructured":"Sidana S, Ahmed N, Akhtar OS, Heim M, Brazauskas R, Hansen DK, et al. Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma. Blood. 2023;142:1027.","journal-title":"Blood"},{"key":"2482_CR76","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2482_CR77","doi-asserted-by":"crossref","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol 2023: JCO2201365.","DOI":"10.1200\/JCO.22.01365"},{"key":"2482_CR78","doi-asserted-by":"crossref","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 2024;144:2375\u201388.","DOI":"10.1182\/blood.2023023616"},{"key":"2482_CR79","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41:8008.","journal-title":"J Clin Oncol"},{"key":"2482_CR80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371.","journal-title":"Leukemia"},{"key":"2482_CR81","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107\u201316.","journal-title":"Lancet Haematol"},{"key":"2482_CR82","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","volume":"41","author":"BR Dholaria","year":"2023","unstructured":"Dholaria BR, Weisel K, Mateos M-V, Goldschmidt H, Martin TG, Morillo D, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. J Clin Oncol. 2023;41:8003.","journal-title":"J Clin Oncol"},{"key":"2482_CR83","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S2152-2650(24)01842-1","volume":"24","author":"NJ Bahlis","year":"2024","unstructured":"Bahlis NJ, van de Donk N, Reece D, Bhutani M, Dholaria B, D\u2019Souza A, et al. Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study. Clin Lymphoma, Myeloma Leuk. 2024;24:S1.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"2482_CR84","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","volume":"23","author":"S Harrison","year":"2023","unstructured":"Harrison S, Riley CH, Manier S, Yoon S-S, Pinto A, Cazaubiel T, et al. Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses. Clin Lymphoma Myeloma Leuk. 2023;23:S3\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2482_CR85","volume":"8","author":"S Kumar","year":"2024","unstructured":"Kumar S, Berdeja J, Sborov D, Corradini P, Cohen YC, Lesokhin A, et al. Cevostamab in Patients with RRMM who are Triple-Class refractory and Have Received a pror BCMA-Targeted ADC or CAR T-cell: Initial Results from the Phase I\/II CAMMA 2 Study. HemaSphere. 2024;8:e104.","journal-title":"HemaSphere"},{"key":"2482_CR86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood"},{"key":"2482_CR87","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/bloodadvances.2024012773","volume":"8","author":"B Puertas","year":"2024","unstructured":"Puertas B, Fernandez-Sanchez A, Alejo E, Rey-Bua B, Martin-Lopez AA, Perez-Lopez E, et al. A research center\u2019s experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma. Blood Adv. 2024;8:3478\u201387.","journal-title":"Blood Adv"},{"key":"2482_CR88","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","volume":"142","author":"AJ Jakubowiak","year":"2023","unstructured":"Jakubowiak AJ, Anguille S, Karlin L, Chari A, Schinke C, Rasche L, et al. Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 Study. Blood. 2023;142:3377.","journal-title":"Blood"},{"key":"2482_CR89","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","volume":"142","author":"J Matous","year":"2023","unstructured":"Matous J, Biran N, Perrot A, Berdeja JG, Dorritie K, Elssen JV, et al. Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: safety and preliminary efficacy results from the Phase 1b monumenTAL-2 Study. Blood. 2023;142:1014.","journal-title":"Blood"},{"key":"2482_CR90","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min C-K, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8002.","journal-title":"J Clin Oncol"},{"key":"2482_CR91","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","volume":"142","author":"L Sanchez","year":"2023","unstructured":"Sanchez L, Schinke C, Krishnan A, Berdeja JG, van de Donk NW, Mateos MV, et al. Clinical Outcomes of Subsequent Therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 MonumenTAL-1 Study. Blood. 2023;142:2007.","journal-title":"Blood"},{"key":"2482_CR92","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(24)01939-6","volume":"24","author":"L Joiner","year":"2024","unstructured":"Joiner L, Costa L, Giri S, Ravi G, Godby K, Hagedorn C, et al. BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) progressing after GPRC5D-Directed therapy. Clin Lymphoma Myeloma Leuk. 2024;24:S61\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2482_CR93","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jha2.572","volume":"3","author":"M Baljevic","year":"2022","unstructured":"Baljevic M, Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Lentzsch S, et al. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem. 2022;3:1270\u20136.","journal-title":"EJHaem"},{"key":"2482_CR94","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1111\/bjh.16550","volume":"189","author":"A Chari","year":"2020","unstructured":"Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, et al. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020;189:e126\u201330.","journal-title":"Br J Haematol"},{"key":"2482_CR95","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/blood-2022-158180","volume":"140","author":"S Lonial","year":"2022","unstructured":"Lonial S, Abdallah A-O, Anwer F, Badros AZ, Bhutani M, Khan A, et al. Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial. Blood. 2022;140:4398\u2013400.","journal-title":"Blood"},{"key":"2482_CR96","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N. Engl J Med. 2023;389:1009\u201322.","journal-title":"N. Engl J Med"},{"key":"2482_CR97","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"2482_CR98","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"2482_CR99","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2022-160401","volume":"140","author":"KR Reyes","year":"2022","unstructured":"Reyes KR, Liu Y-C, Huang C-Y, Banerjee R, Martin T, Shah N, et al. Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-Targeted CAR-T Therapy. Blood. 2022;140:617\u20139.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02482-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02482-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02482-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:01:24Z","timestamp":1741086084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02482-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2482"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02482-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LJC: Honoraria (Amgen, Bristol-Myers-Squibb, AbbVie, Pfizer, Johnson & Johnson, Adaptive Biotechnologies, Sanofi, Genentech\/Roche), Research Funding (Amgen, Bristol-Myers-Squibb, Johnson & Johnson, AbbVie, Caribou, Gracell, Genentech\/Roche); RB: Honoraria (Bristol-Myers-Squibb, Pfizer, Adaptive Biotechnologies, Caribou, Genentech\/Roche, GSK, Karyopharm, Legend Biotech, Johnson & Johnson, SparkCures), Research Funding (AbbVie, Bristol-Myers-Squibb, Johnson & Johnson, Novartis, Pack Health, Prothena, Sanofi); HM: Honoraria (Bristol-Myers-Squibb, Pfizer, GSK, Karyopharm, AbbVie) Research Funding (Pfizer); SB: Honoraria (AbbVie, Adaptive Biotechnologies, Bristol-Myers-Squibb, Johnson & Johnson, MJH Lifesciences); BD: Honoraria (Sanofi, Johnson & Johnson, Canopy, COTA, Bristol-Myers-Squibb) Research Funding (Amgen, GSK); CN: Honoraria (Johnson & Johnson); JR: Honoraria (Janssen, Bristol-Myers-Squibb, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, AbbVie, Regeneron, Forus, Menarini, Adaptive Biotechnologies); KW:Honoraria (Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda) Research Funding (Amgen, BMS\/Celgene, Janssen, Sanofi; GSK, Abbvie) Consultancy (Abbvie, Amgen, Adaptive Biotech, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda); MJF: Honoraria (Kite\/Gilead, CMS, Novartis, Janssen, Legend, Cytoagents, SITC); JCY: Honoraria (Janssen, Sanofi, Bristol-Myers-Squibb, Regeneron, GSK, Pfizer, Menarini); NWCJvdD: Honoraria (Janssen, Amgen, Celgene, Novartis, Cellectis, Bristol-Myers-Squibb\/Celgene, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Pfizer, AbbVie, Servier) Research Funding (Janssen, Amgen, Bristol-Myers-Squibb\/Celgene, Novartis, Cellectis); NB: Honoraria (AbbVie, Amgen, Bristol-Myers-Squibb, Forus, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda) Research Funding (Pfizer); RP: Honoraria (GSK, Pfizer, Janssen, Bristol-Myers-Squibb, Abbvie, Roche) Research Funding (GSK, Pfizer); W-JC: Honoraria (AbbVie, Amgen, Pfizer, Sanofi, Regeneron, GSK, Novartis) Research Funding (Bristol-Myers-Squibb, Janssen, Novartis); PJH: Advisory Board without honoraria (Antengene, Gilead, iTeos Therapeutics, GSK, Janssen, Pfizer), Research Funding: Novartis; GK: Honoraria (Janssen, Bristol-Myers-Squibb, Sanofi, Kite, Arcellx, Pfizer, Kedrion, Cellectar); PK: Research Funding (Takeda Pharmaceuticals, Celgene, Sanofi, AbbVie, Karyopharm Therapeutics, Sorrento Therapeutics, Ichnos Sciences, Amgen); FS: Honoraria (AbbVie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, Bristol-Myers-Squibb, Novartis, SkyliteDX, Pfizer, Daiki-Sankyo,); JB: Honoraria (AstraZeneca, Bristol-Myers-Squibb, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda) Research Funding (2 Seventy Bio, Abbvie, Amgen, Bristol-Myers-Squibb, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Takeda); HE: Honoraria (Bristol-Myers-Squibb, Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, Roche), Research Funding (BMS\/Celgene, Janssen, Sanofi; GSK, Amgen) Consultancy (Amgen, BMS, Celgene, Janssen, GSK, Novartis, Roche, Sanofi, Takeda); ADC: Honoraria (GSK; Bristol-Myers-Squibb, Janssen, AbbVie, Pfizer, iTeos, Ichnos, Arcellx, Legend; Genentech\/Roche, Novartis, AstraZeneca, Kite); Research Funding (GSK, Genentech, Janssen, BMS); Patent (Novartis); JM: Honoraria (Amgen, Sanofi, Bristol-Myers-Squibb, Janssen, Takeda); YL: Honoraria (Janssen, Sanofi, NexImmune, Caribou, Bristol-Myers-Squibb, Pfizer, Regeneron, Genentech; Sanofi, Regeneron) Research Funding (Janssen, Bristol-Myers-Squibb); TGM: Honoraria (GSK, Sanofi, Amgen, Janssen); AC: Honoraria (AbbVie, Adaptive biotechnologies, Amgen, Angengene, Bristol-Myers-Squibb, Forus, Genentech\/Roche, GSK, Janssen, Karyopharm, Millenium\/Takeda, Sanofi). The remaining authors declare no conflict of interest. The work presented in this manuscript did not receive any financial or material support.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}